[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362215-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362215-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lifetime-risk-of-cancer-in-carriers-of-intermediate-alleles-in-the-htt-gene","Lifetime risk of cancer in carriers of intermediate alleles in the HTT gene","","Lifetime cancer risk was evaluated for carriers of intermediate alleles (IA) in the HTT gene, focusing on CAG repeat lengths within 27–35. The analysis used 8149 participants from the Northern Sweden Health and Disease Study, combining Swedish Cancer Registry records, Hospital Discharge data, and death certificates. Kaplan-Meier and Cox proportional hazards models estimated time to cancer while adjusting for smoking, BMI, and alcohol consumption. Overall, IA carriers did not show a reduced cancer risk, while reduced penetrance alleles suggested possible dose-dependent protection that needs confirmation in larger cohorts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lifetime-risk-of-cancer-in-carriers-of-intermediate-alleles-in-the-htt-gene/362215/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lifetime-risk-of-cancer-in-carriers-of-intermediate-alleles-in-the-htt-gene/362215.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research question of the study?","Question",{"text":63,"@type":64},"The study examines whether carrying an intermediate allele (IA) in the HTT gene confers a reduced lifetime risk of cancer, and also explores associations between CAG repeat length and cancer risk.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was cancer risk measured in the study?",{"text":68,"@type":64},"Cancer diagnoses were retrieved from the Swedish Cancer Registry, the Hospital Discharge Registry, and death certificates. Time to cancer was estimated using Kaplan-Meier curves and Cox proportional hazard models.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about cancer risk in intermediate allele carriers?",{"text":72,"@type":64},"Intermediate allele carriers as a group did not have a reduced cancer risk compared with normal alleles. A reduced penetrance group showed hazard ratio values that were described as similar to full penetrance results, and any protective dose-dependent effect remains to be confirmed.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362215,1790721325,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLifetime risk of cancer in carriers of intermediate alleles in the HTT gene  \nJimmy Sundblom1, Ingvar Bergdahl2, Eva-Lena Stattin3 & Valter Niemelä4􀀍  \nPrevious studies have found a markedly reduced risk of cancer among Huntington’s disease (HD) patients with CAG ≥40, but data on cancer risk at shorter repeat numbers are lacking. The study includes 8149 subjects from Northern Sweden Health and Disease Study. Genotyping yielded a large number of intermediate allele carriers (IA, CAGn 27–35,(n = 497), normal alleles (CAGn 17–26,n = 6584), short alleles (CAG ≤16, n = 169) and 31 subjects with > 35 repeats, including reduced penetrance alleles (36–39; not guaranteed to suffer HD symptoms during a normal lifespan) and HD alleles > 39. Cancer diagnoses were retrieved from the Swedish Cancer Registry and the Hospital Discharge Registry and death certificates. We used Kaplan-Meier curves and Cox proportional hazard models to estimate the time to cancer, on strata of the population created by CAG repeat number intervals. Smoking status, BMI, as well as alcohol consumption were included in the models. 2735 participants (33.6%) had ≥ 1 cancer type. The Hazard-Ratio (HR) for IA carriers compared with normal alleles was similar, 0.97 CI  \n0.82–1.15). The reduced penetrance allele group (CAGn 36–39, n = 29) had HR of 0.54 CI 0.22–1.30 similar to what has been reported with a full penetrance allele. Intermediate allele carriers as a group did not have a reduced risk of cancer. It remains possible that reduced penetrance alleles confer lower risk of cancer, with signs of a dose-dependent protective effect ofCAG repeat length. The latter finding needs to be confirmed in even larger cohorts as these repeat numbers are relatively rare.  \nKeywords Huntington´s disease, Cancer, Intermediate alleles, Reduced penetrance alleles, Genetics  \nHuntington’s disease (HD) is a hereditary neurodegenerative disorder caused by the expansion of CAG trinucleotide repeats within the huntingtin gene (HTT). While the presence of a full mutation (≥ 40 CAG repeats) is well-established as the cause of HD, the health significance of carrying intermediate alleles (IA)—CAG repeat lengths ranging from 27 to 35, remains less studied. IA: s were initially considered non-pathogenic, but emerging evidence suggests their potential impact on disease manifestations similar to that ofHD in rare cases1. Increased lifetime risk of depression has also been reported for individuals with short or long normal alleles2.  \nMany different trinucleotide disorders have been described, and repeated sequences are prevalent in the human genome9. They give rise to disease in different ways, including loss of function, toxic RNA gain of function and repeat sequences translated into pathogenic proteins (as in HD)10.  \nResearch on the effects of genomic repeat sequences may reveal new sources of human phenotypic variability.  \nInterestingly, several studies have rendered evidence supporting an association between HD and decreased risk of cancer3–6. The studies that had access to genotype found no association between CAG repeat number and cancer occurrence5,6. Only one study has reported a modulating effect of IAs (CAGn 27–35) on the risk of developing cancer. This study focused on a cohort of BRCA mutation carriers and found a decreased risk of breast cancer among BRCA carriers who also have an IA7. Prospective studies on IA carriers and their risk of all cancers are lacking. Also, the risk among persons carrying reduced penetrance alleles (not guaranteed to cause symptoms of HD during a normal lifespan) with 36–39 CAG repeats is not known.  \nThe SHAPE study (Swedish-Huntingtin-Alleles-PhenotypE) was designed to investigate the prevalence and potential health consequences ofIAs in the general population in Northern Sweden.  \nAs we have previously reported, the prevalence of IAs in this region is 6.8%8. With this high ","cbCaipcdHw2131h5","https://ap.wps.com/l/cbCaipcdHw2131h5","pdf",1578022,"English","# Introduction\n# Materials and methods\n## Study population and baseline data\n# Statistical analysis\n# Results\n# Discussion","[{\"question\":\"What is the main research question of the study?\",\"answer\":\"The study examines whether carrying an intermediate allele (IA) in the HTT gene confers a reduced lifetime risk of cancer, and also explores associations between CAG repeat length and cancer risk.\"},{\"question\":\"How was cancer risk measured in the study?\",\"answer\":\"Cancer diagnoses were retrieved from the Swedish Cancer Registry, the Hospital Discharge Registry, and death certificates. Time to cancer was estimated using Kaplan-Meier curves and Cox proportional hazard models.\"},{\"question\":\"What did the study find about cancer risk in intermediate allele carriers?\",\"answer\":\"Intermediate allele carriers as a group did not have a reduced cancer risk compared with normal alleles. A reduced penetrance group showed hazard ratio values that were described as similar to full penetrance results, and any protective dose-dependent effect remains to be confirmed.\"}]","Lifetime risk of cancer in carriers of intermediate alleles in the HTT gene | PDF",1790146797,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2e1ac28267aef89fa641c4d9c6ab803.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a61cfcbe0889a54e1ad2f995309bd4a3.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e120b487cd9e43114086516a95d1f4a.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af22d393c47c9bb9a0430e215fd7155b.webp",980,1287]